Bill > HR1332

This bill aims to address the high costs of health care services, prescription drugs, and health insurance coverage in the United States through a variety of reforms across the private insurance market, Medicare and Medicaid programs, and prescription drug competition. Key provisions include: - Establishing an "Invisible High Risk Pool Reinsurance Program" to help stabilize the individual insurance market and imposing a tax on health plans sold through the ACA exchanges. - Changing the permissible age variation in health insurance premium rates. - Repealing the employer health insurance mandate. - Providing greater flexibility for states to obtain waivers under the ACA. - Limiting exclusivity periods for drugs treating rare diseases and biosimilar products. - Requiring the FDA to expedite development and priority review of generic complex drug products. - Repealing the limit on the maximum Medicaid rebate amount for single source and innovator multiple source drugs. - Regulating manufacturer-sponsored copay contributions. - Increasing transparency around 340B drug discount program utilization by hospitals. - Applying Medicare rates to certain highly concentrated hospital markets. - Repealing shared savings incentives from the Medicare Shared Savings Program. - Expanding coverage of telehealth services under Medicare. - Exempting certain value-based arrangements and technologies from Stark Law and Anti-Kickback Statute restrictions. Overall, the bill aims to increase competition, transparency, and flexibility in the health care system to help reduce costs for consumers.

Health and Social Services, Military Affairs and Security

https://www.congress.gov/bill/116th-congress/house-bill/1332/all-info